The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Amryt boost as epidermolysis bullosa drug rival fails Amicus Therapeutics pulled EB drug after it failed to meet certain targets in a trial A child’s hand, showing the blistering caused by Epidermolysis Bullosa (EB). The condition causes the skin layers and internal body linings to separate, meaning sufferers blister painfully at the slightest touch. Photograph: Dave Meehan Thu, Sep 14, 2017, 20:40 Irish woundcare group Amryt has become the front-runner in the race to find a treatment for epidermolysis bullosa (EB), known as butterfly disease which causes skin in mainly young patients to blister at the slightest touch. Rival Amicus Therapeutics, which had been ahead of Amryt, has pulled its drug after it failed to meet certain targets in a Phase III trial. Amryt, which commenced its trial earlier this year, is expected to report interim data in the first half of 2018. Goodbody analyst Andrew Young said Amryt’s AP101 drug was a gel that only needs to be applied when dressings are changed every three or four days, as recommended for EB patients. Amicus’s water-based cream required patients to change dressings daily and the company indicated that this may have been a factor in its failure to hit targets for wound closure in patients within three months. Amicus said it had no further plans to invest in further studies or commercialisation of its drug, SD-101. There are currently no approved therapies for EB.
Nope ur right.. Got my figures wrong...i think it was close to €750,000 at 4..equivalent to .32 pence We also have to factor in that Birken AG pumped in €50 million into Episalvan before the merger.
both invested over €1 million at 24 pence back when it merged.Cathal Friel bought out older investors at close to 28 pence prior to merger. So even though they have executed their plan better than expected none of the big boys have made money here.
I think the market makers might be hiding some trades this morning.
I also asked about Lujuxta for other kinds of cholesterol and was given the same answers. Basically he said statins covers most cholesterol issues.
I did... I was told that the cost would be exorbitant for lesser diseases. Im thinking if and when they get FDA approval Imlan might be marketed as Episalvan lite. I got the impression that they dont want ro outsource Imlan because the chemical formula is similar to Episalvan.
Actually meant gene therapy (:
I actually talked to management about the cell therapy and was told that its definately very much hit and miss.Meaning life and death but most of these poor unfortunates have no choice as the condition is a death sentence anyway. Gel on the lesions would still be necessary in any case,I was told.
Definitely creeping up under the radar.
'Investors had been “very cautious” about Amicus’s EB program, expressing concern about the trial design and market opportunity, Leerink Partners LLC analyst Joseph Schwartz said in a report to clients.' Can anyone explain why? Because AP101 is a better design?
SEPTEMBER 13, 2017 / 11:26 AM / UPDATED 16 HOURS AGO Amicus abandons wound treatment, focus shifts to future trial data Manas Mishra (Reuters) - Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer’s expanding pipeline. Amicus’s shares rose as much as 6 percent in morning trading, recovering from a nearly 15 percent slide before the bell The company’s wound drug, SD-101, failed to meet the main goals in a late-stage trial testing the treatment in patients with epidermolysis bullosa (EB), a rare, genetic skin disease that causes severe blisters and currently has no approved treatment. But analysts appeared optimistic about results from Amicus’s upcoming trial testing a treatment for another genetic disorder, and said investor expectations from the SD-101 trial had been muted. Investors had been “very cautious” about Amicus’s EB program, expressing concern about the trial design and market opportunity, Leerink Partners LLC analyst Joseph Schwartz said in a report to clients. Amicus is in the early stage of developing treatments for Pompe disease, a genetic disorder, while European and Australian regulators have already approved the use of the company’s drug to treat Fabry disease, another genetic ailment. “(The failed SD-101 trial) serves more as a clearing event ahead of upcoming Pompe data and Fabry program progress,” Cowen and Co analyst Ritu Baral said. In another sign of progress for Amicus’s pipeline, the U.S. Food and Drug Administration (FDA) in June gave the company the go-ahead to apply to market its Fabry disease drug, migalastat. That green light followed the FDA’s demand in November for Amicus to conduct another late-stage study of migalastat. Amicus said SD-101, when compared with a placebo, did not show a statistical significance in reducing the time taken for wounds to close in patients with EB. The number of patients whose wounds had closed after taking Amicus’s drug, SD-101, was also not different from the number of patients on a placebo whose wounds had closed, the company said. Shares of Cranbury, New Jersey-based Amicus were up 4.4 percent at $13.87 in morning trade. The stock has more than doubled in value since the beginning of the year.
Now that's a good find. Thanks... From Reuters... Amicus abandons wound treatment.
Insider buying? Are they frozen because of the phase 3 trial? I notice Chairman Harry doesn't own any.
Market is saying prove it!
On the same page John..I have a cousin who was an assistant trainer for his brother Eddie.Worked in the yard for years with minimal pay rises.Now he's with Nicky Henderson with a much better quality of life.
Funny you should mention O'Leary,I'm from Mullingar so I see him in his fatherly role at the weekend.Not the hard nosed business man that is his public image.He completely shuts down just the kids and their sports. Would I want him in politics NO.He would make Trump look like Bernie Sanders!
If i were you I would hold off, this is going lower!
I see u skirted the issue! Please tell me what Simon and Leo have contributed to modern day Ireland.Some might say Simon did a good job in Agriculture but imo that was EU policy. Leo has failed miserably in all his roles as a minister. Im not saying the Left are the answer but they are a necessity to keep the Capitalist's at no cost in place. Wallace did build shoes boxes but you probably know the construction federation lobbied to build smaller units.And got their way.